Diaceutics
DXRX · AIM · Health Care · mcap £172m · 203.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 24 Sep 26 | Diaceutics and Syndax expand Relay partnership
Diaceutics expands Relay partnership with Syndax to support commercialization of acute leukaemia precision medicine. |
+0.8% | |
| 22 Sep 26 | Results | Half-year Results
H1 2026 revenue grew 22% constant currency to £17.5m; ARR up 79% to £29.4m; order book increased 38% to £43.7m. |
+9.4% |
| 20 Aug 26 | Diaceutics and PCC launch NGS Concordance Study
Diaceutics and Precision Cancer Consortium launch NGS Concordance Study to evaluate variant detection across sequencing panels. |
−4.2% | |
| 29 Jul 26 | 75% ARR Growth Drives Revenue & Profit Visibility
H1 2026 revenue £17.5m up 22% at constant currency; ARR up 75% to £28.8m with 91% visibility on FY26 consensus. |
+4.3% | |
| 26 May 26 | Results | Final Results
Revenue grew 20% to £38.4m, Adjusted EBITDA up 80% to £7.6m, return to profitability with strong order book of £38.9m. |
−9.3% |
| 16 Apr 26 | Related Party Transaction - Lease Extension
Belfast headquarters lease extended by five years to August 2036 with annual rent rising to £235,000. |
+0.0% | |
| 15 Jan 26 | Trading update | Full Year 2025 Trading Update
FY 2025 revenues £38.5m (20% growth), returned to profitability, record order book £36.8m, guidance 25% FY 2026 growth. |
+10.2% |
Company filings. Not investment advice.